MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers

The Need

Cancer is a significant health problem and a leading cause of death in developed countries. Solid cancers, including prostate, breast, lung, stomach, colon, and pancreatic cancers, pose particularly challenging diagnostic and treatment obstacles. Early detection of these cancers is crucial for successful outcomes, but current screening methods, like PSA-based testing, suffer from low sensitivity and specificity, leading to missed cases and unnecessary follow-up biopsies.

The Technology

The technology presented here is based on the discovery of specific microRNAs (miRNAs) that show altered expression levels in different solid cancers. MicroRNAs are small, non-coding RNA molecules that regulate gene expression and play essential roles in cellular processes. The technology offers novel methods for diagnosing solid cancers by comparing the levels of specific miRNAs in a patient's test sample to those in a control sample.

Commercial Applications

  1. Early Cancer Detection: The technology enables early and accurate detection of various solid cancers, such as prostate, breast, lung, stomach, colon, and pancreatic cancers.

  2. Personalized Treatment: By identifying specific miRNAs associated with different cancers, the technology facilitates tailored treatment plans, optimizing therapeutic outcomes for individual patients.

  3. Screening and Intervention: The technology aids in identifying individuals with a genetic susceptibility to cancer, enabling more aggressive screening and intervention strategies.


  1. Improved Diagnostic Accuracy: The technology's high sensitivity and specificity lead to a reduction in false negatives and false positives, enhancing the accuracy of cancer diagnosis.

  2. Enhanced Prognosis: Early detection through miRNA-based screening allows for timely intervention, potentially increasing survival rates and improving patient outcomes.

  3. Targeted Therapies: Understanding miRNA-mediated gene regulatory mechanisms opens the door to developing targeted therapies, increasing the effectiveness of cancer treatments.

  4. Non-Invasive Testing: The technology relies on easily accessible samples like blood or tissue, providing a non-invasive and convenient diagnostic option for patients.

  5. Advancements in Cancer Research: The discovery of miRNAs associated with different cancers contributes to a deeper understanding of cancer biology, fostering future research and advancements in oncology.

In summary, this groundbreaking technology harnesses the power of microRNA profiling to revolutionize cancer diagnosis, treatment, and prevention. By identifying specific miRNA markers, it offers early detection, personalized treatment options, and targeted therapies, thereby elevating the standard of cancer care and improving patient outcomes.


Patent # Title Country
8148069 MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers United States of America
9017939 Method for Diagnosing Breast, Colon, Lung and Pancreatic and Prostate Cancer Using miR-21 and miR-17-5P United States of America
9023598 Method for Diagnosing Pancreatic Cancer Using miR-103-1, miR-103-2, miR-24-2 and miR-107 United States of America
9017940 Method for Diagnosing Colon Cancer Using MicroRNA Signatures United States of America
9051618 Method for Diagnosing Lung Cancer Using MicroRNA Signatures United States of America

Loading icon